An Open-label, 2-arm, Single-sequence, Single Oral Dosing, Crossover Clinical Trial to Evaluate Safety and the Pharmacokinetics Between Dapagliflozin, Linagliptin and Metformin in Healthy Adult Subjects
Latest Information Update: 01 Jul 2025
At a glance
- Drugs AJU-A53 (Primary) ; Dapagliflozin (Primary) ; Linagliptin (Primary) ; Metformin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors AJU Pharm
Most Recent Events
- 01 Jul 2025 New trial record